Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 196-201

  Ueki, Keisuke ^a   Mukasa, Akitake ^a   Asai, Akio ^a   Kirino, Takaaki ^a,l   Nishikawa, Ryo ^b   Hirose, Takanori ^b   Nakazato, Yoichi ^c   Hirato, Junko ^c   Funada, Nobuaki ^d   Fujimaki, Takamitsu ^e   Hojo, Shuntaro ^e   Kubo, Osami ^f   Ide, Takafumi ^g   Usui, Masaaki ^h   Ochiai, Chikayuki ⁱ   Ito, Shoichi ^j   Takahashi, Hiroshi ^k  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e TEIKYO UNIVERSITY HOSPITAL   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ Kanto Teishin Hospital   (Japan)

^j TOKYO TEISHIN HOSPITAL   (Japan)

^k TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^l JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2A; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CHROMOSOMAL LOCALIZATION; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC VALUE; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS;

ALLELES; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 19; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGODENDROGLIOMA; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036152488     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. A tiger behind many doors: Multiple genetic pathways to malignant glioma
2. A molecular genetic model of astrocytoma histopathology
3. Progression as exemplified by human astrocytic tumors
4. Genetic alterations in adult diffuse glioma: Occurrence, significance, and prognostic implications
5. Gene amplification in malignant human gliomas: Clinical and histopathologic aspects
6. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2
7. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
8. The retinoblastoma gene is involved in malignant progression of astrocytomas
9. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
10. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
11. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours
12. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas
13. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
14. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
15. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
16. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
17. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
18. Specific chromosomal abnormalities in malignant human gliomas
19. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p
20. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval
21. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens
22. Subsets of glioblastoma multiforme defined by molecular genetic analysis
23. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
24. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
25. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay
26. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
27. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors
28. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
29. New chemotherapy options for the treatment of malignant gliomas
30. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
31. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
32. Clonal expansion of p53 mutant cells is associated with brain tumour progression
33. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation
34. Genetic alterations associated with the evolution and progression of astrocytic brain tumours
35. Molecular genetic evidence for subtypes of oligoastrocytomas
36. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss